The suit is related to an abbreviated new drug application that Par filed with the FDA to market a generic version of DUEXIS tablets.
The lawsuit claims infringement of Horizon’s US patent that is listed in the FDA’s Orange Book and expires 18 July 2026.
The defendants in the lawsuit are Par Pharmaceutical and its parent Par Pharmaceutical Companies.
Par alleged that its generic DUEXIS tablets would not infringe US patent or the patent is invalid or unenforceable.